# Phathom Pharmaceuticals Inc. (PHAT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $9.50, market value $769 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Phathom Pharmaceuticals Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 0.20**. A PEG of 0.20 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 3.2×**. Each dollar of revenue is priced at 3.2×.
- **Free-cash-flow yield: -4.8%** (5-yr avg -29.9%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 82.9%**. Phathom Pharmaceuticals Inc. keeps 82.9% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -17.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -126.3%**. The company reported a net loss over the last twelve months.
- **Return on equity: 50.5%**. A 50.5% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 8.9%**. Return on all capital, debt included, is 8.9%.
- **Return on assets: -38.2%**. Each dollar of assets produces -38.2% of profit.

## Growth
- **Revenue growth (1 yr): 216.9%**. Revenue grew 216.9% over the last year.
- **EPS growth (1 yr): 42.7%**. Earnings per share rose 42.7%, slower than revenue, so margins compressed.

## Financial health
- **Net debt / EBITDA: net cash**. Phathom Pharmaceuticals Inc. holds more cash than debt.
- **Altman Z-score: -3.07**. A Z-score of -3.07 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Phathom Pharmaceuticals Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover Phathom Pharmaceuticals Inc.; the consensus is strong_buy, with an average price target of $21.50 (+126% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -20.8%** (YTD -42.7%, 3-mo -6.2%). The shares are down 20.8% over twelve months including dividends.
- **From 52-week high: -48.1%** (15.7% above the low). Trading 48% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 0.64** (volatility 64%). Beta of 0.64 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PHAT · Page: https://foliofundamentals.com/stocks/phat

Not investment advice.